Retrieved 11 March 2019
Compounded semaglutide, available through licensed telehealth platforms, delivers the same active ingredient at a substantially lower cost than brand-name versions
Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpe S
In many cases, employer-sponsored health plans exclude weight-loss medications altogether, even when obesity-related conditions significantly impact overall health outcomes
That is the GLP-1 before and after story that thousands of people are living right now
Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine in Australia - neither is on the Australian Register of Therapeutic Goods, and the TGA has not evaluated either for safety, quality or effectiveness